Program
IN-207907 120 mg
Also written as “IN-207907 240 mg” and “IN-207907 360 mg”.
Its studies are mostly in Sarcopenia, led by HK inno.N.
Furthest: phase 2, since Jun 16, 20261 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HK inno.N | 11 open or running | phase 2since Jun 16, 2026 | Jun 16, 2026 | Feb 2028phase 2 · NCT07668180 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2026First study: phase 2 study in Sarcopenia in ElderlyFirst studyNCT07668180 · 100 planned
Ahead
- Feb 2028Primary completion: phase 2 study in Sarcopenia in ElderlyNCT07668180
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07668180Sarcopenia in Elderly | 2 | Not yet recruiting | Feb 2028 | 100 |
How it is read
Names in the registry
- “IN-207907 120 mg”, 1 entry
- “IN-207907 240 mg”, 1 entry
- “IN-207907 360 mg”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.